Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Yale University
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Eligibility
- Age range
- 18–90 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion: 1. Male and Female subjects must be ≥18 and \<90 years of age; 2. Able to understand and provide informed consent prior to study procedures 3. Must be in good health Exclusion: 1. Less than 18 years of age; 2. Pregnant or breastfeeding; 3. Any significant systemic illness or unstable medical condition; 4. Pre-existing medical conditions or claustrophobic reactions; 5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months); 6. History of a bleeding disorder or are currently taking anticoagulants.
Interventions
- Drug[ 18F]3F4AP
PET Scan #3
- Drug[18F]MK6240
PET Scan #2
- Drug[11C]PIB
PET Scan #1
Location
- Yale University PET CenterNew Haven, Connecticut